JTE-607
| Overview | |
| Catalog # | bs-83047c-5mg |
| Product Name | JTE-607 |
| Specifications | |
| Storage Buffer | White solid |
| Storage Condition | -20°C |
| Target | |
| Product Information | JTE-607 inhibits inflammatory cytokine production in human peripheral blood mononuclear cells (PBMC’s) without causing immunosuppression: IC50’s = 11 nM (TNF-), 5.9 nM (IL-1), 8.8 nM (IL-6), 7.3 nM (IL-8), and 9.1 nM (IL-10).1 It displayed efficacy in a mouse model of septic shock.2 JTE-607 also showed inhibitory activity against acute myelogenous leukemia cell lines.3,4 Recently, the mechanism of action of JTE-607 (a pro-drug, with the active species being the free acid) has been found to be inhibition of pre-messenger RNA endonuclease Cleavage and Polyadenylation Specificity Factor 3 (CPSF3).5,6 This prevents release of newly synthesized mRNA’s resulting in read-through transcription and the formation of DNA-RNA hybrid R-loop structures. Transcripts down-regulated by JTE-607 were related to DNA damage-based phenotype |
| Description | CAS Number: 188791-09-5 Chemical Name: Ethyl (2S)-2-[[3,5-Dichloro-2-hydroxy-4-[2-(4-methylpiperazin-1-yl)ethoxy]benzoyl]amino]-3-phenylpropanoate dihydrochloride Molecular weight: 597.36 Formula: C25H31Cl2N3O5·2HCl Solubility: DMSO (25 mg/ml) Physical Properties: White solid Purity: 98% by HPLC NMR (Conforms) |